Catalyst Wire Dossier Catalyst Wire Dossier

Tumor Infiltrating Lymphocytes (TIL) therapy with CISH CRISPR editing

· Intima Bioscience, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Tumor Infiltrating Lymphocytes (TIL) therapy with CISH CRISPR editing, covering 2026-02-23 to 2026-02-23. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering [Phase 1, Phase 2]

See pricing